Home › Trials › NCT06212999

Evaluating long-term safety and effectiveness of povorcitinib for hidradenitis suppurativa

A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

PHASE3 · Incyte Corporation · NCT06212999

This study is testing if povorcitinib is safe and effective for people with moderate to severe hidradenitis suppurativa who have already tried it for a year in earlier trials.

Quick facts

PhasePHASE3
Study typeInterventional
Enrollment960 (estimated)
Ages18 Years and up
SexAll
SponsorIncyte Corporation (industry)
Drugs / interventionspovorcitinib
Locations172 sites (Phoenix, Arizona and 171 other locations)
Trial IDNCT06212999 on ClinicalTrials.gov

What this trial studies

This study aims to assess the long-term safety and efficacy of povorcitinib in patients with moderate to severe hidradenitis suppurativa who have previously completed a 54-week treatment in earlier Phase 3 studies. Participants will be monitored for their response to the treatment and any potential side effects over an extended period. The study focuses on individuals who have already been part of the initial trials, ensuring a consistent patient population for evaluation.

Who should consider this trial

Good fit: Ideal candidates are individuals who have completed the initial 54-week treatment in the parent studies and meet the inclusion criteria.

Not a fit: Patients who are pregnant, breastfeeding, or those who may face undue safety risks from participation will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new long-term treatment option for patients suffering from moderate to severe hidradenitis suppurativa.

How similar studies have performed: Other studies have shown promising results with similar treatments for hidradenitis suppurativa, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302).
* Agreement to use contraception.
* Willing and able to comply with the study protocol and procedures.
* Further inclusion criteria apply.

Exclusion Criteria:

* Participation in the extension study could expose the participant to an undue safety risk.
* Women who are pregnant (or who are considering pregnancy) or breastfeeding.
* Further exclusion criteria apply.

Where this trial is running

Phoenix, Arizona and 171 other locations

+122 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Hidradenitis Suppurativa, Hidradenitis, Acne inversa, HS, Povorcitinib, Long-Term Extension, INCB054707

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.